CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years. Both technologies are experiencing exponential growth. While CAR T-cell therapy holds great promise in the fight against cancer, significant hurdles remain preventing realization of its full potential. Several innovative approaches are under investigation to overcome these hurdles. The present article provides a peek into this area of innovation by focusing on the invention described in a recently published patent application, WO/2018/115887, relating to novel CAR T-cells engineered using CRISPR.
The post CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsenal appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Other Barks & Bites for Friday, July 26: New Group Registration for Frequently Updated News Websites, Trade Secret Claims Against TikTok Survive Dismissal, and USPTO’s Estoppel Provisions in IPR Proceedings Upheld
- Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
- CAFC Committee Recommends Another Year of Sanctions Against Newman
- Massie Tells House IP Subcommittee Witnesses He’s ‘Appalled’ By Proposals to Rein in ITC’s Patent Powers
- CAFC Invalidates Remaining Claim on Data Transmission Patent, Remands Substitute Claims for Collateral Estoppel Determination